Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• HER2 positive breast cancer accounts for approximately 20% of all breast cancer cases.
• Historically, HER2 positive breast cancer had the worst prognosis among subtypes.
• The advent of HER2-targeted therapies has significantly improved patient outcomes.

Purpose of the Study:

• To review current management strategies for HER2 positive breast cancer.
• To highlight advancements in diagnosis and treatment for this specific breast cancer subtype.
• To discuss therapeutic options for both local and metastatic HER2 positive disease.

Main Methods:

• Review of existing literature on HER2 positive breast cancer management.
• Analysis of diagnostic guidelines for HER2 status determination.
• Synthesis of data on treatment efficacy for local and metastatic disease.

Main Results:

• Accurate HER2 status determination is crucial for effective treatment selection.
• Local HER2 positive breast cancer management now features less aggressive, highly effective approaches with high cure rates.
• Metastatic HER2 positive breast cancer shows a median survival of approximately 5 years, with new molecules offering disease control in complex scenarios.

Conclusions:

• Targeted therapies have transformed the prognosis of HER2 positive breast cancer.
• Precise diagnostic methods and updated guidelines are essential for optimal patient care.
• Ongoing research continues to yield novel therapeutic options for managing this disease effectively.